Drug Trial Radar · NCT06053424
Positron Emission Tomography (PET) Study of Changes in [11C]AZ14132516 Uptake Following Administration of AZD7798 to Healthy Participants and Patients With Crohn's Disease
Last checked: Nov 19, 2026Latest source record: Aug 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
13
Actual
Start
Sep 25, 2023
Primary completion
Oct 8, 2024
Study completion Oct 8, 2024
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Sep 25, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 20 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to measure the changes in small bowel uptake of radioligand \[11\^C\]AZ14132516 after intravenous (IV) administration of single and repeat doses of AZD7798 in healthy participants and participants with Crohn's disease. Study details include: * The study duration will be variable (adaptive design). * For Panels 1-5, there will be 5 in-person study visits: 1 screening visit, 1 visit for the baseline PET examination, 1 residential (24 hour) visit for AZD7798 administration and 2 visits for repeated PET examinations. There will be a final follow-up virtual visit (telephone call). * For Panel 6, there will be 7 in-person study visits: 1 screening visit, 1 visit for the baseline PET examination, 2 residential (24 hour) visits for AZD7798 administration, 1 visit for pharmacokinetic (PK) blood sample and 2 visits for repeated PET examinations. There will be a final follow-up virtual visit.
Conditions
- Crohn's Disease
Interventions
AZD7798Drug
Participants will receive IV infusion of AZD7798 as stated in arm description.
[11C]AZ14132516Drug
Participants will receive IV bolus dose of radioligand \[11\^C\]AZ14132516 as stated in arm description.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage Change in Small Bowel Partition Coefficient (Kp) From Baseline (Positron Emission Tomography [PET]1 Visit) to PET2 VisitTime frame: PET1 visit (baseline; Day -7 to Day -1) and PET2 visit (Day 14 for all panels except Day 2 for Panel 3)
- Percentage Change in Small Bowel Kp From Baseline (PET1 Visit) to PET3 VisitTime frame: PET1 visit (baseline; Day -7 to Day -1) and PET3 visit (Day 42 for all panels except Days 56 and 28 for Panels 2 and 6, respectively)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Research Site
Stockholm, Sweden
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.